Vermillion Company Profile (NASDAQ:VRML)

About Vermillion (NASDAQ:VRML)

Vermillion logoVermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VRML
  • CUSIP: N/A
  • Web:
  • Market Cap: $75.82 million
  • Outstanding Shares: 56,164,000
Average Prices:
  • 50 Day Moving Avg: $1.34
  • 200 Day Moving Avg: $1.74
  • 52 Week Range: $0.76 - $2.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.44
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.05 million
  • Price / Sales: 24.86
  • Book Value: $0.08 per share
  • Price / Book: 16.88
  • EBIDTA: ($10,500,000.00)
  • Net Margins: -372.05%
  • Return on Equity: -215.26%
  • Return on Assets: -121.77%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 3.21%
  • Quick Ratio: 3.16%
  • Average Volume: 40,223 shs.
  • Beta: 2.42
  • Short Ratio: 16.56

Frequently Asked Questions for Vermillion (NASDAQ:VRML)

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.04). The company had revenue of $0.90 million for the quarter. Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. View Vermillion's Earnings History.

Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?

1 equities research analysts have issued 12 month target prices for Vermillion's shares. Their forecasts range from $1.75 to $1.75. On average, they anticipate Vermillion's stock price to reach $1.75 in the next year. View Analyst Ratings for Vermillion.

Who are some of Vermillion's key competitors?

Who are Vermillion's key executives?

Vermillion's management team includes the folowing people:

  • James T. LaFrance, Chairman of the Board
  • Valerie Barber Palmieri, President, Chief Executive Officer
  • Fred Ferrara, Chief Operating Officer
  • Donald G. Munroe Ph.D., Senior Vice President - Business Development, Chief Scientific Officer
  • Eric J. Schoen, Chief Accounting Officer, Vice President - Finance
  • James S. Burns, Independent Director
  • Veronica G. H. Jordan Ph.D., Independent Director
  • David R Schreiber, Independent Director
  • Carl Severinghaus, Independent Director
  • Eric K. Varma M.D., Independent Director

Who owns Vermillion stock?

Vermillion's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.36%), Birchview Capital LP (4.07%), Vanguard Group Inc. (1.03%), Cannell Peter B & Co. Inc. (0.60%), M&T Bank Corp (0.41%) and Trellus Management Company LLC (0.21%). Company insiders that own Vermillion stock include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Institutional Ownership Trends for Vermillion.

Who sold Vermillion stock? Who is selling Vermillion stock?

Vermillion's stock was sold by a variety of institutional investors in the last quarter, including Birchview Capital LP and Trellus Management Company LLC. View Insider Buying and Selling for Vermillion.

Who bought Vermillion stock? Who is buying Vermillion stock?

Vermillion's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Vermillion stock in the last two years include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Insider Buying and Selling for Vermillion.

How do I buy Vermillion stock?

Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vermillion's stock price today?

One share of Vermillion stock can currently be purchased for approximately $1.35.

MarketBeat Community Rating for Vermillion (NASDAQ VRML)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vermillion (NASDAQ:VRML) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.75 (29.63% upside)

Analysts' Ratings History for Vermillion (NASDAQ:VRML)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Canaccord GenuityReiterated RatingBuy$2.50 -> $1.75LowView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Vermillion (NASDAQ:VRML)
Earnings by Quarter for Vermillion (NASDAQ:VRML)
Earnings History by Quarter for Vermillion (NASDAQ VRML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.04)($0.04)$0.90 millionViewListenView Earnings Details
5/18/2017Q1 2017($0.04)($0.05)$0.73 millionViewN/AView Earnings Details
11/10/2016Q316($0.06)($0.07)$0.62 millionViewN/AView Earnings Details
8/10/2016Q216($0.09)($0.07)$0.71 millionViewListenView Earnings Details
5/16/2016Q116($0.09)($0.09)$0.51 millionViewListenView Earnings Details
3/24/2016Q415($0.10)$1.20 million$0.36 millionViewListenView Earnings Details
11/12/2015Q315($0.10)($0.10)$0.57 million$0.33 millionViewListenView Earnings Details
8/13/2015Q215($0.08)($0.11)$1.50 million$535.00 millionViewListenView Earnings Details
5/11/2015Q115($0.10)($0.10)$0.81 million$0.95 millionViewListenView Earnings Details
3/25/2015Q414($0.08)($0.11)$1.59 million$1.57 millionViewListenView Earnings Details
11/14/2013Q3($0.10)$319.00 million$330.00 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.11)$0.32 million$0.23 millionViewListenView Earnings Details
5/15/2013Q1 2013($0.15)($0.17)$0.30 million$0.33 millionViewListenView Earnings Details
11/12/2012Q312($0.21)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vermillion (NASDAQ:VRML)
Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS


Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vermillion (NASDAQ:VRML)
Insider Ownership Percentage: 3.67%
Institutional Ownership Percentage: 35.57%
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Institutional Ownership by Quarter for Vermillion (NASDAQ:VRML)
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Valerie Barber PalmieriInsiderBuy719$1.39$999.41View SEC Filing  
8/23/2017Valerie Barber PalmieriInsiderBuy768$1.30$998.40View SEC Filing  
5/17/2017Valerie Barber PalmieriInsiderBuy555$1.80$999.00View SEC Filing  
2/17/2017Larry N FeinbergInsiderBuy617,731$1.40$864,823.40View SEC Filing  
2/13/2017Eric SchoenSVPBuy3,347$1.40$4,685.80View SEC Filing  
2/13/2017Jack W SchulerMajor ShareholderBuy974,081$1.40$1,363,713.40View SEC Filing  
2/13/2017Valerie Barber PalmieriCEOBuy10,042$1.40$14,058.80View SEC Filing  
2/13/2017Veronica Gh JordanDirectorBuy6,695$1.40$9,373.00View SEC Filing  
1/28/2016Jack W SchulerMajor ShareholderBuy1,493$1.60$2,388.80View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy3,700$1.57$5,809.00View SEC Filing  
1/21/2016Jack W SchulerMajor ShareholderBuy30,700$1.46$44,822.00View SEC Filing  
1/19/2016Jack W SchulerMajor ShareholderBuy57,749$1.45$83,736.05View SEC Filing  
1/15/2016Jack W SchulerMajor ShareholderBuy8,400$1.56$13,104.00View SEC Filing  
7/14/2015Larry N FeinbergInsiderBuy512,043$1.96$1,003,604.28View SEC Filing  
12/23/2014Jack W SchulerMajor ShareholderBuy1,288,339$1.44$1,855,208.16View SEC Filing  
12/23/2014Larry N FeinbergInsiderBuy972,222$1.44$1,399,999.68View SEC Filing  
12/19/2014Peter S RoddyDirectorBuy16,502$1.44$23,762.88View SEC Filing  
11/21/2014Valerie Barber PalmieriCOOBuy3,500$1.51$5,285.00View SEC Filing  
11/20/2014James T LafranceInsiderBuy27,907$1.44$40,186.08View SEC Filing  
11/20/2014Valerie Barber PalmieriCOOBuy30,000$1.44$43,200.00View SEC Filing  
11/19/2014James T LafranceInsiderBuy41,615$1.43$59,509.45View SEC Filing  
11/18/2014Eric SchoenCAOBuy5,000$1.42$7,100.00View SEC Filing  
11/20/2013William B CreechVPBuy2,000$2.33$4,660.00View SEC Filing  
6/11/2013William B CreechVPBuy10,000$3.18$31,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vermillion (NASDAQ:VRML)
Latest Headlines for Vermillion (NASDAQ:VRML)
DateHeadline logoIs It Too Late To Buy Vermillion Inc (VRML)? - September 23 at 10:49 AM logoETFs with exposure to Vermillion, Inc. : September 19, 2017 - September 19 at 8:30 PM logoVermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 19 at 9:22 AM logoVermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell - September 1 at 10:56 AM logoVermillion, Inc. (VRML) Receives "Buy" Rating from Canaccord Genuity - August 30 at 4:56 PM logoCritical Analysis: Vermillion (VRML) & CareDx (CDNA) - August 25 at 2:12 PM logoCareDx (CDNA) vs. Vermillion (VRML) Critical Comparison - August 18 at 10:46 AM logoEdited Transcript of VRML earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 13 at 7:34 AM logoVermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates - August 10 at 6:21 PM logoVermillion Reports Second Quarter 2017 Results - August 10 at 9:32 AM logoVermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call - August 5 at 8:22 AM logoVermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th - August 2 at 8:35 AM logoFinancial Survey: Veracyte (VCYT) and Vermillion (NASDAQ:VRML) - August 1 at 8:46 AM logoAnalyzing Veracyte (VCYT) & Vermillion (VRML) - July 31 at 2:23 PM logoVermillion, Inc. (NASDAQ:VRML) Downgraded to "Sell" at ValuEngine - July 28 at 10:26 PM logoVermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th - July 28 at 9:47 AM logoVermillion (NASDAQ:VRML) vs. InVitae Corp (NVTA) Head-To-Head Survey - July 24 at 2:14 PM logoVermillion (VRML) vs. Lion Biotechnologies (IOVA) Head-To-Head Comparison - July 20 at 6:27 PM logo Vermillion, Inc. (NASDAQ:VRML) Receives Average Recommendation of "" from Analysts - July 17 at 8:14 PM logoCritical Survey: Vermillion (VRML) vs. InVitae Corp (NVTA) - July 14 at 12:08 AM logoETFs with exposure to Vermillion, Inc. : July 11, 2017 - July 12 at 9:05 AM logoAffymetrix (AFFX) versus Vermillion (VRML) Critical Contrast - July 1 at 10:04 PM logoVermillion, Inc. (VRML) Upgraded at ValuEngine - June 2 at 8:04 PM logoVermillion, Inc. (VRML) Short Interest Up 10.5% in May - May 28 at 7:06 AM logoETFs with exposure to Vermillion, Inc. : May 15, 2017 - May 15 at 7:44 PM logoVermillion, Inc. :VRML-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 3:29 PM logoVermillion, Inc. (VRML) Issues Earnings Results - May 12 at 12:38 PM logoInvestor Network: Vermillion, Inc. to Host Earnings Call - May 12 at 4:13 AM logoVermillion Reports First Quarter 2017 Results - May 12 at 4:13 AM logoVermillion reports 1Q loss - May 12 at 4:13 AM logoEdited Transcript of VRML earnings conference call or presentation 11-May-17 12:30pm GMT - May 12 at 4:13 AM logoVermillion (VRML) Receiving Positive Press Coverage, Analysis Shows - May 3 at 3:52 PM logoVermillion, Inc. (VRML) Short Interest Update - April 29 at 7:06 AM logoVermillion (VRML) Getting Favorable Media Coverage, Report Shows - April 28 at 1:38 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vermillion, Inc. - (VRML) - April 28 at 10:34 AM logoVermillion to Report First Quarter 2017 Financial Results and Host Investor Conference Call on May 11 - April 26 at 5:09 PM logoSomewhat Negative News Coverage Extremely Likely to Affect Vermillion (VRML) Stock Price - April 25 at 3:30 PM logoVermillion (VRML) Getting Negative Media Coverage, Report Finds - April 19 at 8:23 AM logoAfter raising $2 million, Austin's Consortia Health tackles problems that might make some blush - April 15 at 7:00 PM logoETFs with exposure to Vermillion, Inc. : April 5, 2017 - April 7 at 1:24 PM logoVERMILLION, INC. Files SEC form 10-K, Annual Report - April 1 at 9:38 AM logoEdited Transcript of VRML earnings conference call or presentation 29-Mar-17 8:30pm GMT - March 30 at 8:18 AM logoASPiRA Labs Announces TriCare South Contract - March 30 at 8:18 AM logoQ4 2016 Vermillion Inc Earnings Release - Before Market Open - March 29 at 10:17 AM logoVermillion Announces Publication of Ovarian Cancer Symptoms Index Study - March 29 at 10:17 AM logoVermillion, Inc. (VRML) Scheduled to Post Quarterly Earnings on Wednesday - March 28 at 8:23 AM logoVermillion to Report Fourth Quarter and Full Year 2016 Financial Results and Host Investor Conference Call on March 29, 2017 - March 16 at 6:31 AM logoVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - March 13 at 8:09 PM logoVermillion, Inc. (VRML) Sees Large Decline in Short Interest - March 13 at 8:23 AM logoASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1® Access to Over 12 Million Beneficiaries - March 6 at 7:53 PM



Vermillion (VRML) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff